No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CMPX Compass Therapeutics
- 1.470
- -0.020-1.34%
Close Apr 19 16:00 ET
- 1.450
- -0.020-1.36%
Post 19:32 ET
202.26MMarket Cap-4454P/E (TTM)
1.583High1.410Low232.98KVolume1.470Open1.490Pre Close343.61KTurnover0.23%Turnover RatioLossP/E (Static)137.59MShares3.62052wk High1.36P/B151.20MFloat Cap1.15052wk Low--Dividend TTM102.85MShs Float8.800Historical High--Div YieldTTM11.59%Amplitude1.150Historical Low1.474Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics with a Buy and maintains $10 price target.
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics (CMPX) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment. CTX-8371 is a bispecific checkpoint inhibitor. The study includes f
Express News | Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of Ctx-8371 in Patients With Solid Tumors
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics
Comments
$Compass Therapeutics(CMPX.US$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
1
ColumnsToday's pre-market stock movers: AMD, SBUX, ABNB, MRNA and more
Gainers:
• $Livent(LTHM.US$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US$ +7.18% (matched estimates wi...
• $Livent(LTHM.US$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US$ +7.18% (matched estimates wi...
26
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg